Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

American journal of physiology. Endocrinology and metabolism - 1 Dec 2006

Alba Maria, Fintini Danilo, Sagazio Alessia, Lawrence Betty, Castaigne Jean-Paul, Frohman Lawrence A, Salvatori Roberto

Abstract excerpt

Although the majority of children with isolated growth hormone (GH) deficiency have a good growth response to GH-releasing hormone (GHRH), the use of this therapeutic agent is limited by its very short half-life. Indeed, we have shown that, in mice with GHRH gene ablation (GHRH knockout; GHRHKO), even twice-daily injections of a GHRH analog are unable to normalize growth. CJC-1295 is a synthetic GHRH analog that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Development
Share to Femur

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Growth

Share to Growth Hormone

Share to Growth Hormone-Releasing Hormone

Share to Pituitary Gland

Share to Prolactin

Source

Identifiers

PMID: 16822960
DOI: 10.1152/ajpendo.00201.2006

Genes

GHRH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.PMID 16822960Read ↗

Partial reversibility of growth hormone (GH) deficiency in the GH-releasing hormone (GHRH) knockout mouse by postnatal treatment with a GHRH analog.Semantic proximity Read ↗

A Mouse with Targeted Ablation of the Growth Hormone-Releasing Hormone Gene: A New Model of Isolated Growth Hormone DeficiencySemantic proximity Read ↗

Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indicationsSemantic proximity Read ↗

Deletion, but not antagonism, of the mouse growth hormone receptor results in severely decreased body weights, insulin, and insulin-like growth factor I levels and increased life span.Semantic proximity Read ↗

Growth hormone-releasing hormone disruption extends lifespan and regulates response to caloric restriction in mice.Semantic proximity Read ↗

New insights into growth hormone actionSemantic proximity Read ↗

Disruption of the GH Receptor Gene in Adult Mice Increases Maximal Lifespan in FemalesSemantic proximity Read ↗

Growth hormone excess and the development of growth hormone receptor antagonists.Semantic proximity Read ↗

GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function.Semantic proximity Read ↗

The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling.Semantic proximity Read ↗

Growth hormone releasing hormone expression during postnatal development in growth hormone-deficient Ames dwarf mice: mRNA in situ hybridization.Semantic proximity Read ↗

Lessons learned from studies with the growth hormone receptor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.